HUTCHMED Receives Complete Response Letter from the US FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors

HUTCHMED (China) Limited announced that the US Food and Drug Administration has issued a Complete Response Letter regarding the New Drug Application for surufatinib for the treatment of pancreatic and extra-pancreatic neuroendocrine tumors.